Assessment of selected cytokines, proteins, and growth factors in the peritoneal fluid of patients with ovarian cancer and benign gynecological conditions

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 471-485

  Chudecka Głaz, Anita Monika ^a   Cymbaluk Płoska, Aneta Alicja ^a   Menkiszak, Janusz Leszek ^a   Pius Sadowska, Ewa ^a   Machaliński, Bogusław Bronisław ^a   Sompolska Rzechuła, Agnieszka ^b   Rzepka Górska, Izabella Anna ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b WEST POMERANIAN UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Ascites; Cytokines; GDF 15; Ovarian cancer; SCF; Tumor growth factor

Indexed keywords

CYTOKINE; GROWTH DIFFERENTIATION FACTOR 15; GROWTH FACTOR; HUMAN EPIDIDYMIS PROTEIN 4; INTERLEUKIN 6; INTERLEUKIN 8; OSTEONECTIN; OSTEOPROTEGERIN; PROTEIN; STEM CELL FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; CANCER CELL; CANCER PROGNOSIS; CANCER STAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; FEMALE GENITAL TRACT TUMOR; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVARY CANCER; PERITONEAL FLUID; PERITONEUM METASTASIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT;

EID: 84923375939     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S73438     Document Type: Article

References (69)

1. Matte I, Lane D, Laplante C, Rancourt C, Piché A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res. 2012;2(5):566–580.
2. Sadłecki P, Walentowicz-Sadłecka M, Szymański W, Grabiec M. Comparison of VEGF, IL-8 and β-FGF concentrations in the serum and ascites of patients with ovarian cancer. Ginekol Pol. 2011;82(7):498–502. Polish.
3. Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013;3:256.
4. Peng P, Yan Y, Keng S. Exosomes in the ascites of ovarian cancer patients: origin and effects an anti-tumor immunity. Oncol Rep. 2011;25(3):749–762.
5. Castells M, Thibault B, Mery E, et al. Ovarian ascites–derived Hospicells promote angiogenesis via activation of macrophages. Cancer Lett. 2012;326(1):59–68.
6. Reinartz S, Schumann T, Finkernagel F, et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 2014;134(1):32–42.
7. Dijkgraaf EM, Heusinkveld M, Tummers B, et al. Chemotherapy alters monocyte differentiation to favour generation of cancer–supporting M2 macrophages in the tumor microenvironment. Cancer Res. 2013;73(8):2480–2492.
8. Dubeau L. The cell origin of ovarian epithelial tumors an the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol. 1999;72(3):437–442.
9. Shih I, Kurman R. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511–1518.
10. Ayhan A, Gultekin M, Taskiran C, et al. Ascites and epithelial ovarian cancers: a reappraisal with respect to differ aspects. Int J Gynecol Cancer. 2007;17(1):68–75.
11. Lane D, Matte I, Rancourt C, Piché A. Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of trail–induced apoptosis. J Ovarian Res. 2012;5:34.
12. Lane D, Matte I, Laplante C, Garde-Granger P, Rancourt C, Piché A. Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK) and Akt signalling in ovarian cancer cells to attenuate TRAIL-induced apoptosis. J Ovarian Res. 2013;6(1):82.
13. Wang Y, Li L, Guo X, et al. Interleukin-6 signaling regulates anchorage–independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine. 2012;59(2):228–236.
14. Wang Y, Niu XL, Qu Y, et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett. 2010;295(1):110–123.
15. Macciò A, Madeddu C. Inflammation and ovarian cancer. Cytokine. 2012;58(2):133–147.
16. Browne A, Sriraksa R, Guney T, et al. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. Cytokine. 2013;64(1):413–421.
17. Ataie-Kachoie P, Morris DL, Pourgholami MH. Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies. PLoS One. 2013;8(4):e60817.
18. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38(7):904–910.
19. Cohen S, Bruchim I, Graiver D, et al. Platiunum–resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2. J Mol Med (Berl). 2013;91(3):357–368.
20. DeLong ER, DeLong DM, Clarke-Pearson DeL. Comparing the Areas Under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach. Biometrics. 1988;44(3):837–845.
21. Woolery KT, Kruk PA. Ovarian epithelial stromal interactions: role of interleukins 1 and 6. Obstet Gynecol Int. 2011;2011:358493.
22. Rath KS, Funk HM, Bowling MC, Richards WE, Drew AF. Expression of soluble interleukin-6 receptor in malignant ovarian tissue. Am J Obstet Gynecol. 2010;203 (3):230.e1–e8.
23. Wang Y, Xu RC, Zhang XL, et al. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine. 2012;59(1):145–155.
24. Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer. 2011;11:210.
25. Liu K. Stem cell factor (SCF)-kit mediated phosphatidylinositol 3 (PI3) kinase signalling during mammalian oocyte growth and early follicular development. Front Biosci. 2006;11:126–135.
26. Zhang W, Stoica G, Tasca SI, Kelly KA, Meininger CJ. Modulation of tumor angiogenesis by stem cell factor. Cancer Res. 2000;60(23):6757–6762.
27. Organ C, Hines SJ, Kornstein MJ, Krystal GW. Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Factor Differ. 1995;6(6):769–779.
28. Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G. Coexpression for the c-kit receptor and the stem cell factor in gynaecological tumors. Cancer Res. 1994;54(11):3049–3053.
29. Liu L, Zhang X, Du C, et al. MEK1-independent activation of MAPK and MEK1-dependent activation of p70 S6 kinase by stem cell factor (SCF) in ovarian cancer cells. Biochem Biophys Res Commun. 2009;382(2):385–389.
30. Lawicki S, Gacuta-Szumarska E, Będkowska GE, Szmitkowski M. Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian patients. Growth Factors. 2012;30(6):357–366.
31. Bootcov MR, Bauskin AR, Valenzuela SM, et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A. 1997;94(21):11514–11519.
32. Fairlie WD, Moore AG, Bauskin AR, Russel PK, Zhang HP, Breit SN. MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J Leucoc Biol. 1999;65(1):2–5.
33. Bauskin AR, Brown DA, Kuffner T, et al. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res. 2006;44(10):4938–4936.
34. Griner SE, Joshi JP, Nahta R. Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion. Biochem Pharmacol. 2013;85(1):46–58.
35. Kim JS, Baek SJ, Sali T, Eling TE. The conventional nonsteroidal anti-inflammatory drug sulindac sulifide arrests ovarian cancer cell growth via expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther. 2005;4(3):487–493.
36. Staff AC, Trovik J, Eriksson AG, et al. Elevated plasma growth differentiation factor-15 correlates with lymph nodes metastases and poor survival in endometrial cancer. Clin Cancer Res. 2011;17(14):4825–4833.
37. Trovik J, Salvesen HB, Cuppens T, Amant F, Staff AC. Growth differentiation factor-15 as biomarker in uterine sarcomas. Int J Gynecol Cancer. 2014;24(2):252–259.
38. Carpinelli P, Cappella P, Losa M, et al. GDF15 as a novel biomarker for monitoring danusertib activity. J Mol Biomark Diagn. 2011;S2:001.
39. Bock AJ, Stavnes HT, Kempf T, et al. Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions. Int J Gynecol Cancer. 2010;20(9):1448–1455.
40. Niehrs C. Function and biological roles of Dickkopf family of Wnt modulators. Oncogene. 2006;25(57):7469–7481.
41. Shizhuo W, Tao J, Shulan Z, Bing Z. The expression and significance of Dickkopf-1 in epithelial ovarian carcinoma. Int J Biol Markers. 2009;24(3):165–170.
42. Liu Y, Tang W, Xie L, et al. Prognostic significance of dickkopf-1 overexpression in solid tumors: a meta-analysis. Tumor Biol. 2014;35(4):3145–3154.
43. Kalloger SE, Köbel M, Leung S, et al. Calculator for ovarian carcinoma subtype prediction. Modern Pathol. 2011;24(4):512–521.
44. Wang S, Zhang S. Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. Clin Exp Metastasis. 2011;28(6):581–591.
45. Jiang T, Wang S, Huang L, Zhang S. Clinical significance of serum DKK-1 in patients with gynecological cancer. Int J Gynecol Cancer. 2009;19(7):1177–1781.
46. Kim DY, Kim MJ, Kim HB, et al. Suppression of multidrug resistance by treatment with TRAIL in human ovarian and breast cancer cells with high level of c-Myc. Biochim Biophys Acta. 2011;1812(7):796–805.
47. Merino D, Lalaoui A, Morizot E, Solary O, Micheau O. TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets. 2007;11(10):1299–1314.
48. Syed V, Mukherjee K, Godoy-Tundidor S, Ho SM. Progesterone induced apoptosis in TRAIL – resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J Cell Biochem. 2007;102(2):442–452.
49. Lane D, Robert V, Grondin R, Rancourt C, Piché A. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer. 2007;121(6):1227–1237.
50. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is biomarker for ovarian carcinoma. Cancer Res. 2003;63(13):3695–3700.
51. Plotti F, Capriglione S, Terranova C, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer. Tumor Biol. 2012;33(6):2117–2123.
52. Chudecka-Głaz A, Rzepka-Górska I, Wojciechowska I. Human epididymal protein 4 (HE4) is a novel biomarker and promising prognostic factor in ovarian cancer patients. Eur J Gynaecol Oncol. 2012;33(4):382–390.
53. Kong S, Han M, Yoo H, et al. Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. Ann Surg Oncol. 2012;19(5):1707–1712.
54. Dougall WC. Moleculat pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res. 2012;18(2):326–335.
55. McGonile JS, Giachelli CM, Scatena M. Osteoprotegrin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis. 2009;12(1):35–46.
56. Bao LH, Sakaguchi H, Fujimoto J, Tamaya T. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci. 2007;14(3):373–381.
57. Denhardt DT, Guo X. Osteopontin: a protein with diverse function. FASEB J. 1993;7(15):1475–1482.
58. Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of Osteopontin as clinical cancer marker. Oncol Rep. 2011;25(2):433–441.
59. Mrochem-Kwarciak J, Mrochen-Domin I, Wojcieszek A, et al. Usefulness of osteopontin (OPN) determinations in ovarian cancer patients who underwent first-line chemotherapy. Ginekol Pol. 2011;82(12):911–917. Polish.
60. Moszyński R, Szubert S, Szpurek D, Michalak S, Sajdak S. Role of osteopontin in differential diagnosis of ovarian tumors. J Obstet Gynecol Res. 2013;39(11):1518–1525.
61. Matsuura M, Suzuki T, Saito T. Osteopontin is new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci. 2010;101(8):1828–1833.
62. Kato N, Motoyama T. Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1β expression. Histopathol. 2008;52(6):682–688.
63. Davidson B, Holth A, Moripen L, Trope’ CG, Shih IeM. Osteopontin expression in ovarian carcinoma effusions is related to improve clinical outcome. Hum Pathol. 2011;42(7):991–997.
64. Brown TJ, Shaw PA, Karp X, Huynh MH, Begley H, Ringuette MJ. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol Oncol. 1999;75(1):25–33.
65. Yiu GK, Chan WY, Ng SW, et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol. 2001;159(2):609–622.
66. Chen J, Wang M, Xi B, et al. SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer. PLoS One. 2012;7(8):e42413.
67. Said N, Najwer I, Motamed K. Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor–dependent survival signalling in ovarian cancer. Am J Pathol. 2007;170(3):1054–1063.
68. Said NA, Elmarakby AA, Imig JD, Fulton DJ, Motamed K. SPARC ameliorates ovarian cancer-associated inflammation. Neoplasia. 2008;10(10):1092–1104.
69. Said N, Motamed K. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol. 2005;167(6):1739–1752.